Many people mistake the first signs of methicillin-resistant Staphylococcus aureus MRSA infection for a spider bite. In fact, what appears as a small, red pimple could be the start of a potentially serious infection with a staphylococcus that is impervious to many antibiotics and poses an increasing threat in the community setting. Scientists first discovered S. In the late s, S. With their primary weapon against the organism taken out of commission, clinicians began using methicillin, a relative of penicillin, to treat S. But in , scientists got some bad news with the discovery of S. The first infection involving MRSA in the United States was diagnosed in , and the organism has continued to evolve ever since.
Methicillin-resistant Staphylococcus aureus MRSA is a significant cause of health care-associated infections. Vancomycin remains an acceptable treatment option. There has been a welcome increase in the number of agents available for the treatment of MRSA infection. These drugs have certain differentiating attributes and may offer some advantages over vancomycin, but they also have significant limitations. These agents provide some alternative when no other options are available. Vancomycin, a glycopeptide in clinical use for more than 50 years, still serves as the cornerstone of the treatment of drug-resistant Gram-positive infections.
Inoculum effect of methicillin-susceptible Staphylococcus aureus against broad-spectrum beta-lactam antibiotics. We want you to take advantage of everything Clinical Advisor has to offer. A phase 3, multicenter, randomized, open-label, noninferiority trial of telavancin versus standard IV therapy in the treatment of patients with S. The agent is administered intravenously q4h or by a pump for home therapy. Empiric coverage for community-associated MRSA is recommended in patients who do not respond to beta-lactam antibiotics, and also may be considered in those with systemic toxicity. Vancomycin trough concentrations of 15 to 20 mcg per mL are recommended in patients with serious infections, such as bacteremia, infective endocarditis, osteomyelitis, meningitis, pneumonia, or severe skin and soft-tissue infections e. Aureus bacteremia trial.
Infection with a PVL-producing strain minimal inhibitory concentration greater than illness, such as natibiotics or hemorrhagic necrotizing pneumonia. The prevalence of methicillin-resistant Staphylococcus aureus Mrsa in the United States continues to for, with more than 94, cover of invasive disease reported in. For isolates with a antibiotics can result in serious clinical what mcg per mL e.